Aegean Airlines S.A.

AEGN.AT Q2 2026

Reported: 2026-09-17

Aegean Airlines’ broadly flat market reaction of -1.8% reflects a mixed first half: revenue grew, but profitability deteriorated sharply and 2026 capacity growth has been reduced materially from the original plan. Investors appear focused on lower margins, Middle East disruption and fuel-cost pressure despite management’s expectation for slightly higher Q3 revenue per ASK.

Key takeaways

Q2 revenue increased 3% to approximately €495–496 million, while EBITDA fell 12% to €99 million, EBIT declined 29% to €44 million and pretax profit dropped nearly 70% to €23 million.
First-half revenue rose 4% to €817 million, but EBITDA decreased 7% to €145 million; the company reported a €3.3 million after-tax loss versus €48 million profit last year.
Capacity growth has been scaled back: the initial 2026 ASK growth target of 7–9% has been reduced, with Q3 ASKs expected to rise only 2.5% on average versus the previously indicated 6% summer growth.
Q3 passenger numbers were up just under 5% through August, supported by the larger A321neo fleet, while management expects revenue per ASK to be marginally above last year.
Liquidity remained approximately €950–956 million after repaying a €200 million bond and paying slightly over €80 million in dividends; grounded aircraft peaked at 14–15 and is expected to decline substantially by summer 2027, with none remaining by end-2027.

View recap

Bioceres Crop Solutions Corp.

BIOX Q4 2026

Reported: 2026-09-17

Investors focused on Bioceres’ 18% full-year revenue decline and continued earnings pressure, sending the stock down 9.9% after results. While fourth-quarter revenue stabilized and cost cuts restored modestly positive EBITDA, reported gross profit fell and management did not provide a clear near-term recovery catalyst.

Key takeaways

Full-year continuing-operations revenue declined 18% to approximately $238 million, with weakness concentrated in international operations, crop protection, and the reconfigured seed business.
Fourth-quarter revenue was broadly flat at $55.9 million versus $55.4 million a year earlier; crop nutrition grew 36%, led by microbeaded fertilizer, but this was offset by lower crop protection and seed revenue.
Fourth-quarter reported gross profit fell 6% to $12.7 million, with gross margin of 22.8%, including an approximately $4 million nonrecurring inventory-obsolescence adjustment.
Cost reductions improved fourth-quarter adjusted EBITDA by roughly $10 million year over year, from negative $9.6 million to positive $0.6 million; full-year adjusted EBITDA nevertheless declined to $25.5 million from $28.9 million.
Management cited improving profitability in microbeaded fertilizer, adjuvants, and seed-treatment packs, but inoculants and remaining seed operations continued to weigh on reported performance.

View recap

Forgent Power Solutions, Inc.

FPS Q4 2026

Reported: 2026-09-17

Forgent’s shares rose 21.6% after record Q4 results and a substantial expansion in demand visibility. The key positives were revenue and margin acceleration, bookings of $1.5 billion, and backlog reaching $3 billion as the company enters fiscal 2027.

Key takeaways

Q4 revenue increased 94% year over year to $462 million; adjusted EBITDA rose 163% to $113 million, with margin expanding 200 basis points sequentially to 24.4%.
Adjusted net income increased 275% to $77 million. Full-year revenue reached $1.42 billion, up 89%, while adjusted EBITDA rose 91% to $323 million.
Bookings reached a record $1.5 billion, up 375% year over year and 73% sequentially; the 3.3x book-to-bill ratio was also a company record.
Year-end backlog increased 256% year over year and 53% sequentially to $3 billion, with Powertrain Solutions representing approximately 40% of backlog.
Management plans additional capacity investment in Tijuana and accelerated hiring to support the expected production ramp, while citing direct orders from a Frontier AI lab and an MSA with a hyperscaler as new customer-access milestones.

View recap

High Tide Inc.

HITI Q3 2026

Reported: 2026-09-17

High Tide’s Q3 results were positive but the market reaction was muted, with the stock up 2.3% after earnings. Profitability and cash generation improved materially, although the transcript does not provide enough detail to establish whether the reported performance changed expectations for forward growth or margins.

Key takeaways

Operating income rose 43% sequentially and 133% year-over-year to CAD 8.7 million.
Adjusted net income increased 186% sequentially and 157% year-over-year to CAD 2.2 million, excluding the favorable fair value change in derivative liability.
Record reported net income was CAD 12.7 million, partly aided by that derivative-liability fair value change.
Q3 free cash flow was CAD 7 million, lifting cash by CAD 10.6 million during the quarter; the company also cited CAD 25 million of undrawn revolver capacity and no meaningful debt maturities for three years.
Cabana Club membership reached 2.73 million, while the Canadian store base stood at 232 locations; management cited an approximate CAD 800 million revenue annual run rate company-wide.

View recap

IP Group Plc

IPO.L Q2 2026

Reported: 2026-09-17

IP Group’s shares rose 4.7% after the half-year update, reflecting further NAV growth, strong cash realizations, and positive de-risking of its Pfizer obesity royalty exposure. Progress was broad-based, although the portfolio remains exposed to clinical, regulatory, and commercial risks.

Key takeaways

NAV per share increased approximately 3% to £1.14, taking NAV above £1 billion; NAV per share subsequently reached approximately £1.17 as of 11 September.
Cash proceeds totaled £69 million in the first half—slightly above the full-year 2025 figure—with a further £17 million generated since June and gross cash of £239 million at period-end.
The Pfizer obesity royalty interest rose £27 million to just over £150 million following positive berobenatide data and progression of the berobenatide/amylin combination into Phase IIb.
Portfolio companies raised more than £500 million of third-party capital, with IP Group contributing approximately 5%, providing external validation of continued funding access.
Pfizer is progressing 10 Phase III studies in 2026, with potential launch targeted for 2028; however, IP Group continues to apply probability-weighted valuation given clinical, regulatory, and commercial uncertainties.

View recap

SEALSQ Corp Ordinary Shares

LAES Q2 2026

Reported: 2026-09-17

SEALSQ shares fell 5.6% after earnings, indicating investors were more concerned about the delayed commercialization of its post-quantum products and the timing uncertainty around future growth than reassured by strong first-half revenue and margin expansion. Management expects initial QS7001 and QVault TPM revenue only late in the second half of 2026, with more meaningful contributions pushed to 2027.

Key takeaways

First-half revenue rose 131% year over year to $11.2 million, including approximately $2.5 million from six months of IC’Alps contribution.
Gross profit increased 233% to $5.4 million, with gross margin expanding to approximately 48%.
Post-quantum commercialization remains early-stage: more than 150 customers and prospects are engaged, but only over 30 are actively evaluating or integrating QS7001 and QVault TPM.
Initial QS7001 and QVault TPM revenue is expected late in 2H 2026; timing remains dependent on certification, customer validation, integration, and procurement cycles, with more meaningful revenue expected from 2027.
Liquidity was substantial at more than $486 million in cash equivalents and restricted cash as of June 30, while the commercial pipeline exceeded $225 million through 2029, including more than $100 million tied to post-quantum projects.

View recap

Trip.com Group Limited

TCOM Q2 2026

Reported: 2026-09-17

Trip.com’s shares rose 3.5% after earnings, indicating investors viewed the quarter favorably despite a more challenging travel environment. The strongest signals were continued international momentum, including high-double-digit inbound revenue growth and more than 50% growth on its international OTA platform.

Key takeaways

Second-quarter group net revenue totaled RMB 15.7 billion.
Inbound travel revenue increased at a high-double-digit year-over-year rate, supported by demand from APAC, Europe and the Americas.
Revenue on the international OTA platform increased more than 50% year over year, driven by higher transaction value and favorable mix.
Management highlighted pressure from elevated fuel prices and airfares, with longer-haul demand affected and travel shifting toward shorter-haul destinations.
AI-assisted orders through TripGenie increased approximately 400% year over year; nearly 60% of interactions were booking related.

View recap

Earnings Recaps

Aegean Airlines S.A.

Bioceres Crop Solutions Corp.

Forgent Power Solutions, Inc.

High Tide Inc.

IP Group Plc

SEALSQ Corp Ordinary Shares

Trip.com Group Limited

Community

Earnings Recaps

Aegean Airlines S.A.

Bioceres Crop Solutions Corp.

Forgent Power Solutions, Inc.

High Tide Inc.

IP Group Plc

SEALSQ Corp Ordinary Shares

Trip.com Group Limited

Community

Trending This Week

Notifications